What is William Blair's Estimate for ALNY FY2024 Earnings?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) - William Blair upped their FY2024 EPS estimates for Alnylam Pharmaceuticals in a research report issued on Sunday, January 12th. William Blair analyst M. Minter now anticipates that the biopharmaceutical company will post earnings of ($2.01) per share for the year, up from their prior estimate of ($2.12). William Blair has a "Outperform" rating on the stock. The consensus estimate for Alnylam Pharmaceuticals' current full-year earnings is ($2.21) per share. William Blair also issued estimates for Alnylam Pharmaceuticals' Q4 2024 earnings at ($0.48) EPS.

Several other brokerages also recently issued reports on ALNY. Raymond James increased their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an "outperform" rating in a research report on Friday, November 1st. Canaccord Genuity Group lifted their price target on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a "buy" rating in a research note on Friday, November 1st. Scotiabank upped their price objective on Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the stock a "sector outperform" rating in a research report on Friday, November 1st. Barclays increased their price objective on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an "overweight" rating in a report on Friday, November 1st. Finally, Piper Sandler restated an "overweight" rating and issued a $296.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. One analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $298.61.

Alnylam Pharmaceuticals Stock Up 4.4 %

Shares of ALNY traded up $10.50 on Wednesday, hitting $251.01. The company's stock had a trading volume of 870,422 shares, compared to its average volume of 692,514. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. The firm has a market capitalization of $32.38 billion, a price-to-earnings ratio of -95.81 and a beta of 0.34. The firm's fifty day moving average price is $248.15 and its 200-day moving average price is $259.81. Alnylam Pharmaceuticals has a fifty-two week low of $141.98 and a fifty-two week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to analysts' expectations of $532.91 million. The company's quarterly revenue was down 33.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.15 EPS.

Insider Activity

In related news, CEO Yvonne Greenstreet sold 5,219 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the completion of the sale, the chief executive officer now directly owns 78,880 shares of the company's stock, valued at approximately $19,797,302.40. This trade represents a 6.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Tolga Tanguler sold 1,469 shares of the company's stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $368,689.62. Following the completion of the transaction, the executive vice president now directly owns 13,191 shares in the company, valued at approximately $3,310,677.18. This represents a 10.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,122 shares of company stock valued at $2,540,455 over the last ninety days. 1.50% of the stock is currently owned by company insiders.

Institutional Trading of Alnylam Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Eventide Asset Management LLC grew its position in Alnylam Pharmaceuticals by 157.9% during the third quarter. Eventide Asset Management LLC now owns 224,333 shares of the biopharmaceutical company's stock worth $61,698,000 after buying an additional 137,333 shares in the last quarter. Los Angeles Capital Management LLC lifted its position in shares of Alnylam Pharmaceuticals by 11,433.4% during the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company's stock valued at $37,684,000 after acquiring an additional 135,829 shares during the period. AQR Capital Management LLC lifted its position in shares of Alnylam Pharmaceuticals by 92.5% during the 2nd quarter. AQR Capital Management LLC now owns 271,619 shares of the biopharmaceutical company's stock valued at $65,862,000 after acquiring an additional 130,482 shares during the period. Deerfield Management Company L.P. Series C acquired a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter worth $29,111,000. Finally, Telemark Asset Management LLC bought a new position in shares of Alnylam Pharmaceuticals in the third quarter worth $27,503,000. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.